Ability of Cystatin C to Detect Changes in Glomerular Filtration Rate After ACE Inhibition in Patients with Uncomplicated Type 1 Diabetes

REFERENCES

• Jerums G, Premaratne E, Panagiotopoulos S, Clarke S, Power DA, MacIsaac RJ. New and old markers of progression of diabetic nephropathy. Diabetes Res Clin Pract 2008; 82(Suppl. 1):S30–S37.
   Google Scholar
• Cherney DZ, Scholey JW, Miller JA. Insights into the regulation of renal hemodynamic function in diabetic mellitus. Curr Diabetes Rev 2008; 4(4):280–290.
   PubMedGoogle Scholar
• Ficociello LH, Perkins BA, Silva KH. Determinants of progression from microalbuminuria to proteinuria in patients who have type 1 diabetes and are treated with angiotensin-converting enzyme inhibitors. Clin J Am Soc Nephrol 2007; 2(3):461–469.
   PubMed Web of Science ®Google Scholar
• Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77(6):1925–1930.
   PubMed Web of Science ®Google Scholar
• Zatz R, Meyer TW, Rennke HG, Brenner BM. Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci USA 1985; 82(17):5963–5967.
   PubMed Web of Science ®Google Scholar
• Hostetter TH, Troy JL, Brenner BM. Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int 1981; 19(3): 410–415.
   PubMed Web of Science ®Google Scholar
• Cherney DZ, Sochett EB, Miller JA. Gender differences in renal responses to hyperglycemia and angiotensin-converting enzyme inhibition in diabetes. Kidney Int 2005; 68(4):1722–1728.
   PubMed Web of Science ®Google Scholar
• Sochett EB, Cherney DZ, Curtis JR, Dekker MG, Scholey JW, Miller JA. Impact of renin angiotensin system modulation on the hyperfiltration state in type 1 diabetes. J Am Soc Nephrol 2006; 17(6):1703–1709.
   PubMed Web of Science ®Google Scholar
• Artunc FH, Fischer IU, Risler T, Erley CM. Improved estimation of GFR by serum cystatin C in patients undergoing cardiac catheterization. Int J Cardiol 2005; 102(2):173–178.
   PubMed Web of Science ®Google Scholar
• Cherney DZ, Sochett EB, Dekker MG, Perkins BA. Ability of cystatin C to detect acute changes in glomerular filtration rate provoked by hyperglycaemia in uncomplicated type 1 diabetes. Diabet Med 2010; 27(12):1358–1365.
   PubMed Web of Science ®Google Scholar
• Mingels A, Jacobs L, Kleijnen V, Wodzig W, Dieijen-Visser M. Cystatin C a marker for renal function after exercise. Int J Sports Med 2009; 30(9):668–671.
   PubMed Web of Science ®Google Scholar
• Malyszko J, Bachorzewska-Gajewska H, Poniatowski B, Malyszko JS, Dobrzycki S. Urinary and serum biomarkers after cardiac catheterization in diabetic patients with stable angina and without severe chronic kidney disease. Ren Fail 2009; 31(10):910–919.
   PubMed Web of Science ®Google Scholar
• Kato K, Sato N, Yamamoto T, Iwasaki YK, Tanaka K, Mizuno K. Valuable markers for contrast-induced nephropathy in patients undergoing cardiac catheterization. Circ J 2008; 72(9): 1499–1505.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Okura T, Kurata M. Valsartan reduces serum cystatin C and the renal vascular resistance in patients with essential hypertension. Clin Exp Hypertens 2006; 28(5):451–461.
   PubMed Web of Science ®Google Scholar
• Janickova Zdarska D, Zavadova E, Kvapil M. The effect of ramipril therapy on cytokines and parameters of incipient diabetic nephropathy in patients with type 1 diabetes mellitus. J Int Med Res 2007; 35(3):374–383.
   PubMed Web of Science ®Google Scholar
• Cherney DZ, Miller JA, Scholey JW. The effect of cyclooxygenase-2 inhibition on renal hemodynamic function in humans with type 1 diabetes. Diabetes 2008; 57(3):688–695.
   PubMed Web of Science ®Google Scholar
• Cherney DZ, Scholey JW, Nasrallah R. Renal hemodynamic effect of cyclooxygenase 2 inhibition in young men and women with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol 2008; 294(6):F1336–F1341.
   Google Scholar
• Cherney DZ, Konvalinka A, Zinman B. Effect of protein kinase Cbeta inhibition on renal hemodynamic function and urinary biomarkers in humans with type 1 diabetes: a pilot study. Diabetes Care 2009; 32(1):91–93.
   PubMed Web of Science ®Google Scholar
• Miller JA, Curtis JR, Sochett EB. Relationship between diurnal blood pressure, renal hemodynamic function, and the renin-angiotensin system in type 1 diabetes. Diabetes 2003; 52(7):1806–1811.
   PubMed Web of Science ®Google Scholar
• Schnurr E, Lahme W, Kuppers H. Measurement of renal clearance of inulin and PAH in the steady state without urine collection. Clin Nephrol 1980; 13(1):26–29.
   PubMed Web of Science ®Google Scholar
• Cherney DZ, Lai V, Scholey JW, Miller JA, Zinman B, Reich HN. Effect of direct renin inhibition on renal hemodynamic function, arterial stiffness, and endothelial function in humans with uncomplicated type 1 diabetes: a pilot study. Diabetes Care 2010; 33(2):361–365.
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2 Suppl. 1):S1–S266.
   PubMed Web of Science ®Google Scholar
• Bacchetta J, Cochat P, Rognant N, Ranchin B, Hadj-Aissa A, Dubourg L. Which creatinine and cystatin C equations can be reliably used in children? Clin J Am Soc Nephrol 2011; 6(3): 552–560.
   PubMed Web of Science ®Google Scholar
• Macisaac RJ, Tsalamandris C, Thomas MC. Estimating glomerular filtration rate in diabetes: a comparison of cystatin-C- and creatinine-based methods. Diabetologia 2006; 49(7):1686–1689.
   PubMed Web of Science ®Google Scholar
• Premaratne E, Macisaac R, Finch S, Panagiotopoulos S, Ekinci E, Jerums G. Serial measurements of cystatin C are more accurate than creatinine-based methods in detecting declining renal function in type 1 diabetes. Diabetes Care 2008; 31(5):971–973.
   PubMed Web of Science ®Google Scholar
• Buysschaert M, Joudi I, Wallemacq P, Hermans MP. Performance of serum cystatin-C versus serum creatinine in subjects with type 1 diabetes. Diabetes Care 2003; 26(4):1320.
   PubMed Web of Science ®Google Scholar
• Perkins BA, Ficociello LH, Ostrander BE. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol 2007; 18(4):1353–1361.
   PubMed Web of Science ®Google Scholar
• Stevens LA, Coresh J, Schmid CH. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3418 individuals with CKD. Am J Kidney Dis 2008; 51(3):395–406.
   PubMed Web of Science ®Google Scholar
• Feldman DL, Jin L, Xuan H. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008; 52(1):130–136.
   PubMed Web of Science ®Google Scholar
• Tan GD, Lewis AV, James TJ, Altmann P, Taylor RP, Levy JC. Clinical usefulness of cystatin C for the estimation of glomerular filtration rate in type 1 diabetes: reproducibility and accuracy compared with standard measures and iohexol clearance. Diabetes Care 2002; 25(11):2004–2009.
   PubMed Web of Science ®Google Scholar
• Yuan BH, Robinette JB, Conger JD. Effect of angiotensin II and norepinephrine on isolated rat afferent and efferent arterioles. Am J Physiol 1990; 258(3 Pt 2):F741–F750.
   Google Scholar
• Ito A, Egashira K, Narishige T, Muramatsu K, Takeshita A. Angiotensin-converting enzyme activity is involved in the mechanism of increased endogenous nitric oxide synthase inhibitor in patients with type 2 diabetes mellitus. Circ J 2002; 66(9):811–815.
   PubMed Web of Science ®Google Scholar
• Ohishi K, Carmines PK, Inscho EW, Navar LG. EDRF-angiotensin II interactions in rat juxtamedullary afferent and efferent arterioles. Am J Physiol 1992; 263(5 Pt 2):F900–F906.
   Google Scholar
• Matsuda H, Hayashi K, Wakino S. Role of endothelium-derived hyperpolarizing factor in ACE inhibitor-induced renal vasodilation in vivo. Hypertension 2004; 43(3):603–609.
   PubMed Web of Science ®Google Scholar
• Numabe A, Komatsu K, Frohlich ED. Effects of ANG-converting enzyme and alpha 1-adrenoceptor inhibition on intrarenal hemodynamics in SHR. Am J Physiol 1994; 266(5 Pt 2):R1437–R1442.
   Google Scholar
• Stevens LA, Schmid CH, Greene T. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int 2009; 75(6):652–660.
   PubMed Web of Science ®Google Scholar
• Baxmann AC, Ahmed MS, Marques NC. Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. Clin J Am Soc Nephrol 2008; 3(2):348–354.
   PubMed Web of Science ®Google Scholar
• Knight EL, Verhave JC, Spiegelman D. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004; 65(4):1416–1421.
   PubMed Web of Science ®Google Scholar
• Bokenkamp A, Domanetzki M, Zinck R, Schumann G, Byrd D, Brodehl J. Cystatin C—a new marker of glomerular filtration rate in children independent of age and height. Pediatrics 1998; 101(5):875–881.
   PubMed Web of Science ®Google Scholar
• Perkins BA, Nelson RG, Ostrander BE. Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. J Am Soc Nephrol 2005; 16(5):1404–1412.
   PubMed Web of Science ®Google Scholar